hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06321640 id: IEO 1777 briefTitle: Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. acronym: POSITive overallStatus: RECRUITING date: 2022-07-08 date: 2024-12-31 date: 2025-12-31 date: 2024-03-20 date: 2024-03-20 name: European Institute of Oncology class: OTHER briefSummary: Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which little improvement had been observed for decades such as metastatic melanoma, lung cancer, and lymphoproliferative neoplasms such as chronic lymphoid leukemia or Hodgkin lymphoma. However, major issues remain unsolved, given the frequent occurrence of primary or secondary resistance and the still incomplete understanding of the physiopathology of adverse events, which represent a major cause of morbidity and treatment interruption and often remain difficult to treat and diagnose. In this complex landscape, identifying the best treatment option for each patient remains challenging. For both targeted therapies and Immune checkpoint inhibitors, several biomarkers have been reported, but their implementation in clinical practice is still uncommon, and most of the decision-making process remains based on purely clinical considerations or constraints dictated by the regulatory bodies. Obstacles to biomarker-driven decision making are manifold and include insufficient understanding of the underlying biology, lack of strong evidence on their predictive power and limited tumor sampling, which may be circumvented by non-invasive techniques such as liquid biopsies. conditions: Breast Cancer conditions: Lung Cancer conditions: Melanoma conditions: Head and Neck Cancer conditions: Urothelial Carcinoma conditions: Colorectal Cancer conditions: Liver Metastases conditions: Lung Metastases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 265 type: ESTIMATED name: Cohort A: primarily operable disease, candidate to adjuvant name: Cohort B: locally advanced disease name: Cohort C: metastatic disease name: Cohort D: Progressive disease name: Cohort E: Hematological neoplasms name: Cohort F: Toxicity measure: Percentage of patients in each cohort that will obtain a full "core" omic characterization. measure: Percentage of patients with complete clinical data collection over the expected follow-up time and with successful biobanking. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of oncology status: RECRUITING city: Milan country: Italy name: Giuseppe Curigliano role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321627 id: IEO 1811 briefTitle: Radiosensitivity of HPV-related Tumors: Towards a Genomic Approach acronym: ICARUS overallStatus: RECRUITING date: 2023-04-14 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: European Institute of Oncology class: OTHER briefSummary: The purpose of this study is therefore to analyze the genomic profiles of prognosis and radiosensitivity of Human Papilloma Virus (HPV) related tumors from different body sites (oropharynx, uterine cervix, and anus), considering them as a unified entity regardless of the site of origin within the body. conditions: HPV-Related Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Radiation therapy as curative treatment measure: Disease free survival measure: Genetic patterns of radiosensitivity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Daniela Alterio, MD role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321614 id: 2022098 briefTitle: Deep Learning in Classifying Bowel Obstruction Radiographs overallStatus: ACTIVE_NOT_RECRUITING date: 2022-12-31 date: 2024-04-30 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: The First Affiliated Hospital of Soochow University class: OTHER briefSummary: Background: Accurate labeling of obstruction site on upright abdominal radiograph is a challenging task. The lack of ground truth leads to poor performance on supervised learning models. To address this issue, self-supervised learning (SSL) is proposed to classify normal, small bowel obstruction (SBO), and large bowel obstruction (LBO) radiographs using a few confirmed samples.
Methods: A few number of confirmed and a large number of unlabeled radiographs were categorized based on the ground truth. The SSL model was firstly trained on the unlabeled radiographs, and then fine-tuned on the confirmed radiographs. ResNet50 and VGG16 were used for the embedded base encoders, whose weights and parameters were adjusted during training process. Furthermore, it was tested on an independent dataset, compared with supervised learning models and human interpreters. Finally, the t-SNE and Grad-CAM were used to visualize the model's interpretation. conditions: Digestive System Disease conditions: Polyp of Colon conditions: Bowel Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 4500 type: ESTIMATED measure: Diagnostic and classification performance measure: Visualized interpretation of the self-supervised model sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: TheFirst Affiliated Hospital of Soochow University city: Suzhou state: Jiangsu zip: 215006 country: China lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06321601 id: 20230070 briefTitle: Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2030-04-28 date: 2030-04-28 date: 2024-03-20 date: 2024-03-20 name: Amgen class: INDUSTRY briefSummary: The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV. conditions: Vasculitis studyType: INTERVENTIONAL phases: PHASE3 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Avacopan measure: Proportion of Participants Achieving Disease Remission at Week 26 According to the Pediatric Vasculitis Activities Score (PVAS) measure: Proportion of Participants With Sustained Disease Remission at Week 52 According to the PVAS measure: Plasma Concentrations of Avacopan measure: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE) measure: Proportion of Participants Achieving Disease Remission at Week 26 According to the Birmingham Vasculitis Activity Score (BVAS) measure: Proportion of Participants Achieving Disease Remission at Week 52 According to the BVAS measure: Proportion of Participants With PVAS of 0 Over Time Through Week 52 measure: Proportion of Participants With BVAS of 0 Over Time Through Week 52 measure: Change From Baseline Over 52 Weeks in Urinary Albumin-Creatinine Ratio (UACR) measure: Change From Baseline Over 52 Weeks in Estimated Glomerular Filtration Rate (eGFR) measure: Change From Baseline Over 52 Weeks In Physician Global Assessment (PGA) of Disease Activity measure: Change From Baseline Over 52 Weeks in Pediatric Vasculitis Damage Index (PVDI) measure: Number of Glucocorticoid Dosages Administered measure: Proportion of Participants Across the Taste Score Categories of the TASTY Faces Scale measure: Taste and Acceptability Score of Avacopan per TASTY Faces Scale sex: ALL minimumAge: 6 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06321588 id: GR-2021-12373134 briefTitle: Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment acronym: ADONIS overallStatus: RECRUITING date: 2023-05-10 date: 2026-06-30 date: 2026-06-30 date: 2024-03-20 date: 2024-03-25 name: Azienda Usl di Bologna class: OTHER_GOV briefSummary: The goal of this observational study is to investigate the frequency and the possible pathogenic role of neuronal synaptic antibodies (NSAb) in patients with cognitive impairment (CI). The main questions it aims to answer are:
3. the impact of blood-brain-barrier (BBB) dysfunction on their pathogenicity. conditions: Cognitive Impairment conditions: Dementia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 300 type: ESTIMATED measure: frequency of antibodies against neuronal antigens measure: frequency of antibodies against neuronal antigens measure: creation of a score that predicts the presence of NSAb measure: changes of neurodegeneration biomarkers measure: changes of neurodegeneration biomarkers measure: changes of neuroanatomy measure: changes of neuroanatomy measure: changes of inflammatory biomarkers measure: changes of inflammatory biomarkers measure: changes of brain blood barrier biomarkers measure: changes of brain blood barrier biomarkers sex: ALL minimumAge: 40 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto delle Scienze Neurologiche di Bologna status: RECRUITING city: Bologna zip: 40139 country: Italy name: Maria Pia Giannoccaro, Dr. role: CONTACT phone: 0514966117 email: mariapia.giannoccaro@ausl.bologna.it lat: 44.49381 lon: 11.33875 facility: Istituto Auxologico Italiano IRCCS status: RECRUITING city: Milano zip: 20095 country: Italy name: Federico Verde, Dr. role: CONTACT phone: +3902619112247 email: f.verde@auxologico.it lat: 45.46427 lon: 9.18951 facility: Fondazione IRCCS Istituto Neurologico Carlo Besta status: RECRUITING city: Milano zip: 20133 country: Italy name: Chiara Maria Giulia De Luca, Dr. role: CONTACT phone: +390223942498 email: chiara.deluca@istituto-besta.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321575 id: AVA-CL-5000 briefTitle: The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) acronym: GREAT overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-11 date: 2026-11 date: 2024-03-20 date: 2024-04-01 name: Avantec Vascular class: INDUSTRY name: Bright Research Partners name: Yale Cardiovascular Research Group briefSummary: The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo® Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 15 investigational sites in the U.S. conditions: Peripheral Arterial Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The investigation is a prospective, multicenter, non-randomized, single-arm, open-label pivotal clinical study. primaryPurpose: TREATMENT masking: NONE count: 159 type: ESTIMATED name: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS) measure: Freedom from major adverse events (MAE) measure: Technical success measure: Change in % stenosis in target lesion after treatment with Golazo Peripheral AS measure: Procedural Success Rate measure: Clinical Success Rate measure: Rates of all adverse events classified as MAEs measure: Incidence of minor target limb amputation measure: Incidence of myocardial infarction measure: Incidence of target vessel revascularization (TVR) in the target limb measure: Incidence of angiographic procedural distal embolization in the target limb measure: Time to primary patency of the target vessels measure: Time to assisted primary patency of the target vessels measure: Time to secondary patency of the target vessels sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321562 id: EyeD-010-003 id: 2020-002354-24 type: EUDRACT_NUMBER id: CIV-21-12-038426 type: OTHER domain: EUDAMED briefTitle: Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma overallStatus: RECRUITING date: 2023-03-01 date: 2027-07 date: 2027-07 date: 2024-03-20 date: 2024-03-25 name: EyeD Pharma class: INDUSTRY briefSummary: The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia. The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it.
* if there is any positive effect on the pressure inside the eye. conditions: Primary Open-angle Glaucoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 18 type: ESTIMATED name: TimoD implant name: Injector system measure: Number and proportion of participants experiencing one or more serious adverse events (SAEs) measure: Number and proportion of participants experiencing one or more treatment-emergent adverse events (TEAEs) overall and by dose group sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU - Service d'Ophtalmologie status: RECRUITING city: Liège zip: 4000 country: Belgium name: Nathalie Collignon, Prof. MD. role: PRINCIPAL_INVESTIGATOR lat: 50.63373 lon: 5.56749 facility: Breyer, Kaymak & Klabe Augenchirurgie status: RECRUITING city: Düsseldorf zip: 40212 country: Germany name: Karsten Klabe, MD. role: PRINCIPAL_INVESTIGATOR lat: 51.22172 lon: 6.77616 facility: Universitäts-Augenklinik Heidelberg status: NOT_YET_RECRUITING city: Heidelberg zip: 69120 country: Germany name: Gerd Auffarth, Prof. MD. role: PRINCIPAL_INVESTIGATOR lat: 49.40768 lon: 8.69079 facility: Universitätsaugenklinik Magdeburg status: RECRUITING city: Magdeburg zip: 39120 country: Germany name: Giulia Reineri, MD. role: PRINCIPAL_INVESTIGATOR lat: 52.12773 lon: 11.62916 facility: Augenklinik Sulzbach status: RECRUITING city: Sulzbach zip: 66280 country: Germany name: Karl Boden, MD. role: PRINCIPAL_INVESTIGATOR lat: 49.29882 lon: 7.05696 facility: Universitäts-Augenklinik Tübingen status: RECRUITING city: Tübingen zip: 72076 country: Germany name: Bogomil Voykov, MD. role: PRINCIPAL_INVESTIGATOR lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06321549 id: 202201562B0 briefTitle: New Era of DIEP With Minimally Invasive Mastectomy overallStatus: COMPLETED date: 2022-10-03 date: 2023-10-02 date: 2023-10-02 date: 2024-03-20 date: 2024-03-20 name: Chang Gung Memorial Hospital class: OTHER briefSummary: The free deep inferior epigastric artery perforator (DIEP) flap is the gold standard in autologous breast reconstruction. Asian patients often present with a smaller body mass index with relatively insufficient tissue. To restore appropriate symmetry, a larger flap inset ratio must be transferred. Supercharging of the second vein or inclusion of bilateral pedicle is commonly required. Current paradigm shifts in mastectomy has also resulted in more minimally invasive surgeries (MIS) espousing smaller lateral incisions, leading to a significant change in available recipient vessels. This study aimed to demonstrate our experience in changing strategies of DIEP flaps following the evolution of mastectomy techniques.
Between October 2008 and March 2022, retrospective data was gathered for 278 patients who underwent breast reconstruction surgery utilizing DIEP flaps by a single plastic surgeon. These patients were divided into two distinct groups based on their operation dates, with November 2018 marking a pivotal moment when the first MIS was introduced. conditions: Breast Reconstruction conditions: Mastectomy; Lymphedema studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 278 type: ACTUAL name: The reference point of minimally invasive mastectomy procedure conducted measure: Endoscopy mastectomy measure: Robotic mastectomy measure: Incision measure: Usage of SIEV measure: Inclusion of bipedicle measure: Location of recipient artery/vein measure: Recipient artery/vein selection sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung Memorial Hospital city: Taoyuan zip: 33305 country: Taiwan lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06321536 id: STUDY00007230 id: U54CK000601 type: NIH link: https://reporter.nih.gov/quickSearch/U54CK000601 briefTitle: Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-06 date: 2025-06 date: 2024-03-20 date: 2024-03-20 name: Emory University class: OTHER name: Centers for Disease Control and Prevention briefSummary: REACT is a phase two, open-label, cluster randomized, crossover study of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation. conditions: Multi-Drug Resistant Organism Colonization studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: NONE count: 200 type: ESTIMATED name: Allogeneic Microbiota in Glycerol (9%) (AMG) measure: Difference in number of solicited Adverse Events (AEs) measure: Difference in severity of solicited AEs measure: Difference in number of unsolicited AEs measure: Difference in severity of unsolicited AEs measure: Difference in proportion of participant stool positive cultures for any target MDRO among AMG-treated compared to Observation participants measure: Count of serious AEs (SAEs) measure: Count of AEs of Special Interest (AESIs) measure: Proportion of stool cultures at Day 28 positive for category-specific MDROs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emory University Hospital city: Atlanta state: Georgia zip: 30322 country: United States name: Michael Woodworth, MD role: CONTACT phone: 404-778-1691 lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06321523 id: B3461122 briefTitle: A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-19 date: 2025-04-30 date: 2025-04-30 date: 2024-03-20 date: 2024-04-17 name: Pfizer class: INDUSTRY briefSummary: The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM).
We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective. conditions: Transthyretin Amyloid Cardiomyopathy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 15 type: ACTUAL name: Tafamidis 61 milligrams measure: Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification measure: Change from baseline in six-minute walk test measure: Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) measure: Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration measure: Change From Baseline in Troponin I and Troponin T measure: number of participants with Any Heart Block measure: number of participants with Atrioventricular (AV) block measure: Change From Baseline in Left Ventricular Ejection Fraction measure: Change From a Baseline in Diastolic function grades measure: Change from Baseline in Left Ventricular Wall Thickness measure: Change From Baseline in Global Longitudinal Strain scores measure: Frequency of cardiovascular hospitalizations measure: Frequency of death due to any cause sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pfizer city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06321510 id: A7471070 briefTitle: A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer. overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-15 date: 2025-03-15 date: 2024-03-20 date: 2024-03-22 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer.
All participants in this study had received dacomitinib. Dacomitinib is a tablet that is taken by mouth at home. They continued to take dacomitnib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective. conditions: Lung Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED measure: Percentage of patients with dacomitinib dosage change and reasons measure: Percentage of patients with dacomitinib treatment discontinuation measure: Real-world overall survival (rwOS) measure: Real-world progression-free survival measure: Real-world best objective response rate (rwORR) measure: real-world intracranial response rate (rwIC-ORR) measure: real-world extracranial response rate (rwEC-ORR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321497 id: 85711 briefTitle: Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury overallStatus: RECRUITING date: 2024-02-05 date: 2027-02-28 date: 2028-02-28 date: 2024-03-20 date: 2024-03-20 name: Peninsula Health class: OTHER_GOV name: Monash University name: Baxter Healthcare Corporation briefSummary: Lung protective ventilation with low tidal volumes and low driving pressure are known to reduce mortality in mechanically ventilated patients with acute respiratory failure. This reduction in mortality is known be due to reduction of ventilator induced lung injury that occurs due to high tidal volumes and high driving pressure. When receiving such mechanical ventilation, some patients develop hypercapnia and associated hypercapnic acidosis. Such patients have an increased risk of mortality. While the exact reasons for such increase in mortality is not known, it is recommended to minimise hypercapnia and hypercapnic acidosis during lung protective ventilation. Minimally invasive extracorporeal carbon dioxide removal (ECCO2R) devices are shown to reduce hypercapnia and hypercapnic acidosis. There are several devices that are currently available in the current clinical practice. However, the effect of these devices on reduction in ventilator induced lung injury is not clearly demonstrated. This study aims to assess the use of an ECCO2R device called Prismalung in reducing ventilator induced lung injury. PrismaLung is currently used in our intensive care unit. This assessment is done by measuring interleukins in bronchoalveolar lavage fluid and blood interleukin levels as well as clinical assessment including the reduction of driving pressure. conditions: ARDS, Human studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 15 type: ESTIMATED name: Extracorporeal carbon dioxide removal measure: Reduction in driving airway pressures measure: Reduction in pulmonary inflammation assessed by interleukins in lung sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Frankston Hospital status: RECRUITING city: Frankston state: Victoria zip: 3199 country: Australia name: Ravindranath Tiruvoipati, PhD role: CONTACT phone: 0431279347 email: rtiruvoipati@phcn.vic.gov.au name: Sachin Gupta, FCICM role: CONTACT email: sachingupta@phcn.vic.gov.au lat: -38.14458 lon: 145.12291 hasResults: False